SELLAS Life Sciences Group, Inc. Common Stock

SLSNASDAQ • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
11.29 USD
↘ 0.44 (3.71%)AT CLOSE (11:59 AM EDT)
11.28
↘ 0.01 (0.09%)
POST MARKET (AS OF 07:57 PM EDT)
Post Market
AS OF 07:57 PM EDT
11.28
↘ 0.01 (0.09%)
🔴Market: CLOSED

SELLAS Life Sciences Group, Inc. Common Stock (SLS) trades at $11.29 per share. Technicals currently rate "Strong Sell" while our fundamental analysis reads "Neutral". Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Furthermore, SLS is currently richly valued, trading at a premium to sector peers across key valuation metrics.

Technical & fundamental data as of Sep 15, 2026.

Open?$11.60
High?$11.70
Low?$11.03
Prev. Close?$11.73
Volume?5.2M
Avg. Volume?7.0M
VWAP?$11.26
Rel. Volume?0.75x
Bid / Ask
Bid?$11.26 × 100
Ask?$11.30 × 7.1K
Spread?$0.04
Midpoint?$11.28
Valuation & Ratios
Market Cap?2.3B
Shares Out?201.9M
Float?199.3M
Float %?98.7%
P/E Ratio?N/A
P/B Ratio?16.56
EPS?-$0.16
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyBiotech - Drug Development›Clinical-Stage Platforms
Employees
13
Market Cap
2.4B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.sellaslifesciences.com
Listed
2008-03-12
Address
7 TIMES SQUARE
NEW YORK, NY 10036
Phone: (646) 200-5278
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
65
Short Sent.?
16
Piotroski F-Score?0/9Weak
Altman Z-Score?181.46Safe
Confidence?52%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?29.07%Squeeze Risk
Short Interest?57.9M
Days to Cover?6.9
Free Float199.3M
Avg Daily Volume8.4M
Settlement Date2026-08-31
Financial Health
Current Ratio?18.83Strong
Quick Ratio?18.83Strong
Cash Ratio?18.28Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
10
16.56HIGH▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-60.8CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
7
-23.6%WEAK▾
ROA?
S&P
3
-22.3%WEAK▾
Cash Flow & Enterprise
FCF?$-28423000
Enterprise Value?$2.1B
Fundamentals ratios updated end of day
MarketsMoversWatchlist